Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Canaccord Genuity Growth Conference 2024
15 slides from Pyc Therapeutics's conference presentation, Aug 13, 2024
Slide 1: Canaccord Genuity Growth Conference Presentation
13 August 2024 CANACCORD GENUITY GROWTH CONFERENCE PRESENTATION PERTH, Australia and SAN FRANCISCO, California – 13 August 2024 PYC Therapeutics Limited (ASX:PYC) is pleased to provide a copy of the presentation For personal use only that will be given by PYC’s CEO, Dr Rohan Hockings, at the Canacco
Slide 2: Canaccord Growth Conference - PYC Therapeutics
For personal use only Canaccord Growth Conference PYC Therapeutics August 2024 1
Slide 3: Disclaimer
Disclaimer The purpose of this presentation is to provide an update of the business which are outside PYC’s control. Important factors that could cause For personal use only of PYC Therapeutics Limited (ASX:PYC) [‘PYC’]. These slides have been actual results to differ materially from assumptions or
Slide 4: An introduction to PYC Therapeutics
An introduction to PYC Therapeutics • PYC is a clinical-stage drug discovery and development company with operations in Australia For personal use only and the US • The company is an emerging leader in the field of precision RNA therapies for patients with genetic diseases caused by haploinsufficien
Slide 5: PYC has built a pipeline of first-in-class drug candidates
PYC has built a pipeline of first-in-class drug candidates with disease-modifying potential For personal use only Historical progress Progress expected in 20241 Program Pre-clinical Clinical Prevalence2 VP-0013 Retinitis Pigmentosa Type 11 1 in 100,000 PYC-003 Polycystic Kidney Disease 1 in 1,000 PY
Slide 6: Each asset in the pipeline is a high-propensity and differentiated program
Each asset in the pipeline is a high-propensity and differentiated program that aims to maximise patient-impact PYC’s strategy is built on 4 pillars For personal use only 1 2 3 4 Pillar Single gene disorders Effective in human 3D Haploinsufficient Drugs that overcome ‘mini-organs’ disease mechanism
Slide 7: Drugs targeting single gene disorders are 5x more likely to succeed
1. Drugs targeting single gene disorders are 5x more likely to succeed in clinical development¹ For personal use only “Genetics is so powerful and it provides you with a level of validation around the disease target that is incomparable in drug development. There are so many data points that show th
Slide 8: PYC validates all pipeline candidates in patient-derived models
2. PYC validates all pipeline candidates in patient-derived models before it enters clinical development 1. PYC can create a patient-derived retina Retinitis Pigmentosa type RP11 treated For personal use only 11 (RP11) untreated with VP-001 i. PRPF31 PRPF31 This enables it to determine whether its d
Slide 9: Suitability of RNA therapies for haploinsufficiency is now being recognised
3. The unique suitability of RNA therapies for diseases caused by haploinsufficiency is now being recognised For personal use only “Catalysed by… a few monumental clinical successes, this burgeoning drug class is rapidly expanding and redefining the meaning of a druggable target” PYC THERAPEUTICS 8
Slide 10: PYC's precision therapy pipeline built on proprietary non-viral drug delivery
4. PYC’s precision therapy pipeline has been built on its proprietary non-viral drug delivery technology PYC’s non-viral drug delivery technology achieves ~100x the potency of the ‘naked’ RNA drug in vivo1 For personal use only 1. PYC combines existing RNA drug design 2. PYC’s delivery platform is u
Slide 11: Integration of strategic pillars sets PYC up for clinical success in H2 2024
The integration of these 4 strategic pillars sets PYC up for clinical success in H2 2024 Pre-clinical Clinical For personal use only ? RP11 Patient-derived models Non-human primate RP11 Patient RP11 Patient RP11 Patient Safety and efficacy1 Safety and high drug Safety3 Early efficacy4 Clinical proof
Slide 12: Initial results in patients are encouraging
The initial results in patients are encouraging – multiple patients have improved visual function after a single dose Post single 30 µg treatment with PYC’s drug candidate For personal use only Baseline Week 4 Week 8 Week 16 Multiple patients in PYC’s ongoing Single Ascending Dose study have improve
Slide 13: Results achieved in the absence of any adverse safety signals
These results have been achieved in the absence of any adverse safety signals1 For personal use only • PYC’s drug candidate benefits from a patient-preferred route of administration with a long dosing interval • There have been no Treatment Emergent Serious Adverse Events in any patient observed to
Slide 14: RP11 program has potential to be the first approved therapy
PYC’s Retinitis Pigmentosa Type 11 program has the potential to be the first approved therapy in this indication1 Degenerative sight of an RP11 patient Retinitis Pigmentosa (RP)2,3 For personal use only 6 YEARS OLD • A severe and progressive blinding eye disease that begins in childhood 26 YEARS OLD
Slide 15: First of three human efficacy read-outs anticipated within 18 months
This program is the first of three human efficacy read-outs anticipated within the next 18 months PYC’s path to market is staged with human data read-outs for first-in-class drugs with disease-modifying potential1 For personal use only Program 2024 2025 2026 2027 2028 RP11 Ph1/2 study (underway) Reg
PYC Therapeutics — Canaccord Genuity Growth Conference 2024 on 6ix